Safety and efficacy of the peptide-based therapeutic vaccine for HIV-1, Vacc-4×: a phase 2 randomised, double-blind, placebo-controlled trial

Safety and efficacy of the peptide-based therapeutic vaccine for HIV-1, Vacc-4×: a phase 2 randomised, double-blind, placebo-controlled trial

RB Pollard, JK Rockstroh, G Pantaleo… - The Lancet Infectious …, 2014 - Elsevier

... Vacc-4× was manufactured by Bachem AG (Bubendorf, Switzerland), and distributed in vials
by Penn Pharmaceutical Services Ltd (Gwent, UK). ... in triplicate wells in which the final amount
of each antigen was 1 μg per well (15-mer peptide pools of Vacc-4× peptides, 15-mer ...

Peptide synthesis, peptide modification and peptide library synthesis, please contact:

Eva He

eva@pepmic.com

Pepmic Co., Ltd

www.pepmic.com